AnaptysBio completes separation of First Tracks Biotherapeutics

AnaptysBio (ANAB), announced the completion of its spin-off of First Tracks Biotherapeutics, its former biopharma operations business. “Anaptys begins this next chapter in a virtual business model. We are now exclusively managing royalties from our out-licensed assets, Jemperli and imsidolimab, with streamlined operations requiring limited FTEs, minimal operating expenses and providing a greater than 95% EBIT margin,” said Daniel Faga, president and chief executive officer. “This structure positions us to operate without complexity and deliver maximum value to shareholders.”